Translate page

  Andreas Hochhaus


Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology
Jena University Hospital

Treatment of CML patients after failure of 2 TKIs

  • Choice of an alternative TKI
  • Intolerance after ≥ 2 lines of TKIs
  • Allogeneic HCT in CML in Europe: EDMT Report
  • What is the right dose?  Salvage / frontline
  • Results from the BYOND study and the OPTIC trial
  • Asciminib - an investigational first in class STAMP inhibitor
  • Asciminib study results: phase 1 study / combination with IM, NIL, or DAS,
    ASCEMBL study, phase 3b treatment optimization study
  • Other new drugs in development incl. ELVN-001, PF114, olverembatinib and vodobatinib
  • Conclusion: expanding arsenal to fight failure of TKIs

If you have any questions or comments to the speaker, please email